The Inflation Reduction Act (IRA) contains provisions allowing Medicare to negotiate net prices for prescription drugs, but it remains to be seen whether this will translate into savings for beneficiaries, explained A. Mark Fendrick, MD, co–editor in chief of The American Journal of Managed Care® and director of the V-BID Center at the University of Michigan.
The Inflation Reduction Act (IRA) contains provisions allowing Medicare to negotiate net prices for prescription drugs, but it remains to be seen whether this will translate into savings for beneficiaries, explained A. Mark Fendrick, MD, co–editor in chief of The American Journal of Managed Care® and director of the V-BID Center at the University of Michigan.
Transcript
The IRA includes provisions to lower prescription drug costs in Medicare. How will they impact beneficiaries?
One of the most noteworthy elements of the health care aspects in the Inflation Reduction Act was for the first time giving Medicare the ability to negotiate for prescription drugs. As you know, value-based insurance design focuses more on out-of-pocket costs than total or net cost of drugs. We like to say Americans don't care about health care costs, they care about what it costs them. So the out-of-pocket elements are more important to us at the V-BID Center. But understanding that there is great consternation and a lot of uncertainty regarding how the Medicare negotiations might happen.
It's being phased in over a number of years focusing on some of the most expensive and popular drugs in the beginning. I've read an awful lot about how this actually might work for consumers but also may backfire, in the fact that there are certain ways around this provision and the fact that launch prices may be increased substantially in the first few years to allow those people who do revenue forecasting to make sure that those innovators who make those drugs are able to achieve what they were hoping to make from a financial perspective. But anything that reduces the cost of drugs to patients at the prescription drug counter is very important to us at the V-BID Center. I'm just hopeful that whatever happens regarding the negotiation of the net price of these drugs translates directly into lower out-of-pocket costs for Medicare beneficiaries.
CMS' 340B Repayment Proposal May Harm Vulnerable Hospitals, Reward Those With Higher Revenues
April 26th 2024The 340B hospitals not receiving an offsetting lump-sum payment from CMS following 2018-2022 cuts later ruled unlawful are disproportionately rural, publicly owned, and nonacademic, according to a new study.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Empowering Community Health Through Wellness and Faith
April 23rd 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In the third episode, Camille Clarke-Smith, EdD, MS, CHES, CPT, discusses approaching community health holistically through spiritual and community engagement.
Listen
Dr Dalia Rotstein: Physicians Must Be Aware MS Affects People of All Backgrounds
April 24th 2024Dalia Rotstein, MD, MPH, emphazises the importance of awareness that multiple sclerosis (MS) impacts patients from various backgrounds as clinicians think through ways to improve access to care and research efforts in MS.
Read More